Effects of smoking on clinical treatment outcomes amongst patients with chronic inflammatory diseases initiating biologics: secondary analyses of the prospective BELIEVE cohort study
Scandinavian Journal of Immunology · 2024
DOI: 10.1111/sji.13395 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Scandinavian Journal of Immunology, 2024. Verfasst von Maja Graves Rosenkilde Larsen und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Molecular Diagnostics and Clinical Research Unit, University Hospital of Southern Denmark, Aabenraa, Denmark. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Biological Products, Smoking. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Memorial fund of Knud and Edith Eriksen and the Aage and Johanne Louis-Hansen Foundation, Oak Foundation.
Abstract (Originalsprache)
The prevalence and disease burden of chronic inflammatory diseases (CIDs) are predicted to rise. Patients are commonly treated with biological agents, but the individual treatment responses vary, warranting further research into optimizing treatment strategies. This study aimed to compare the clinical treatment responses in patients with CIDs initiating biologic therapy based on smoking status, a notorious risk factor in CIDs. In this multicentre cohort study including 233 patients with a diagnosis of Crohn's disease, ulcerative colitis, rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis or psoriasis initiating biologic therapy, we compared treatment response rates after 14 to 16 weeks and secondary outcomes between smokers and non‐smokers. We evaluated the contrast between groups using logistic regression models: (i) a “crude” model, only adjusted for the CID type, and (ii) an adjusted model (including sex and age). Among the 205 patients eligible for this study, 53 (26%) were smokers. The treatment response rate among smokers ( n = 23 [43%]) was lower compared to the non‐smoking CID population ( n = 92 [61%]), corresponding to a “crude” OR of 0.51 (95% CI: [0.26;1.01]) while adjusting for sex and age resulted in consistent findings: 0.51 [0.26;1.02]. The contrast was apparently most prominent among the 38 RA patients, with significantly lower treatment response rates for smokers in both the “crude” and adjusted models (adjusted OR 0.13, [0.02;0.81]). Despite a significant risk of residual confounding, patients with CIDs (rheumatoid arthritis in particular) should be informed that smoking probably lowers the odds of responding sufficiently to biological therapy. Registration: Clinical.Trials.gov NCT03173144.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Molecular Diagnostics and Clinical Research Unit, University Hospital of Southern Denmark, Aabenraa, Denmark.
- Section for Biostatistics and Evidence-Based Research, The Parker Institute, Bispebjerg and Frederiksberg Hospital, Frederiksberg, Denmark.
- The Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark.
- Institute of Regional Health Research, University of Southern Denmark, Odense, Denmark.
- Department of Clinical Research, University Hospital of Southern Denmark, Odense, Denmark.
- Research Unit of Rheumatology, Department of Clinical Research, University of Southern Denmark, Odense University Hospital, Odense, Denmark.
ORCID-Profile: Maja Graves Rosenkilde Larsen, Silja Hvid Overgaard, Sofie Ronja Petersen, Karen Mai Møllegaard, Heidi Lausten Munk, Anders Bathum Nexøe, Henning Glerup, Jens Frederik Dahlerup, Christian Lodberg Hvas, Mohamad Jawhara, Ole Haagen Nielsen, Fredrik Olof Bergenheim, Jacob Broder Brodersen, Anette Bygum, Torkell Ellingsen, Jens Kjeldsen, Robin Christensen, Vibeke Andersen
Förderung
- Memorial fund of Knud and Edith Eriksen and the Aage and Johanne Louis-Hansen Foundation
- Oak Foundation
Zitieren
APA
Larsen, M. G. R., Overgaard, S. H., Petersen, S. R., Møllegaard, K. M., Munk, H. L., Nexøe, A. B., Glerup, H., Guldmann, T., Pedersen, N., Saboori, S., Dahlerup, J. F., Hvas, C. L., Andersen, K. W., Jawhara, M., Haagen Nielsen, O., Bergenheim, F. O., Brodersen, J. B., Bygum, A., Ellingsen, T., …, & Andersen, V. (2024). Effects of smoking on clinical treatment outcomes amongst patients with chronic inflammatory diseases initiating biologics: secondary analyses of the prospective BELIEVE cohort study. Scandinavian Journal of Immunology. https://doi.org/10.1111/sji.13395
Vancouver
Larsen MGR, Overgaard SH, Petersen SR, Møllegaard KM, Munk HL, Nexøe AB, et al. Effects of smoking on clinical treatment outcomes amongst patients with chronic inflammatory diseases initiating biologics: secondary analyses of the prospective BELIEVE cohort study. Scandinavian Journal of Immunology. 2024. doi:10.1111/sji.13395
BibTeX
@article{Larsen2024,
author = {Larsen, Maja Graves Rosenkilde and Overgaard, Silja Hvid and Petersen, Sofie Ronja and Møllegaard, Karen Mai and Munk, Heidi Lausten and Nexøe, Anders Bathum and Glerup, Henning and Guldmann, Tanja and Pedersen, Natalia and Saboori, Sanaz and Dahlerup, Jens Frederik and Hvas, Christian Lodberg and Andersen, Karina Winther and Jawhara, Mohamad and Haagen Nielsen, Ole and Bergenheim, Fredrik Olof and Brodersen, Jacob Broder and Bygum, Anette and Ellingsen, Torkell and Kjeldsen, Jens and Christensen, Robin and Andersen, Vibeke},
title = {Effects of smoking on clinical treatment outcomes amongst patients with chronic inflammatory diseases initiating biologics: secondary analyses of the prospective BELIEVE cohort study},
journal = {Scandinavian Journal of Immunology},
year = {2024},
doi = {10.1111/sji.13395}
}
EUVIMED